EP0587806A4 - Therapeutic and diagnostic methods based on neurotrophin-4 expression. - Google Patents

Therapeutic and diagnostic methods based on neurotrophin-4 expression.

Info

Publication number
EP0587806A4
EP0587806A4 EP92914704A EP92914704A EP0587806A4 EP 0587806 A4 EP0587806 A4 EP 0587806A4 EP 92914704 A EP92914704 A EP 92914704A EP 92914704 A EP92914704 A EP 92914704A EP 0587806 A4 EP0587806 A4 EP 0587806A4
Authority
EP
European Patent Office
Prior art keywords
neurotrophin
therapeutic
expression
methods based
diagnostic methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92914704A
Other languages
German (de)
French (fr)
Other versions
EP0587806A1 (en
Inventor
Finn Hallbook
Moliner Carlos Fernando Ibanez
Hakan Bengt Persson
Nancy Ip
George D Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PERSSON, LAURA BETH
PERSSON, MAX PHILIP
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of EP0587806A1 publication Critical patent/EP0587806A1/en
Publication of EP0587806A4 publication Critical patent/EP0587806A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP92914704A 1991-05-21 1992-05-20 Therapeutic and diagnostic methods based on neurotrophin-4 expression. Withdrawn EP0587806A4 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US762674 1985-08-05
US70345091A 1991-05-21 1991-05-21
US703450 1991-05-21
US72925391A 1991-07-12 1991-07-12
US729253 1991-07-12
US73442291A 1991-07-23 1991-07-23
US734422 1991-07-23
US75135691A 1991-08-28 1991-08-28
US751356 1991-08-28
US76267491A 1991-09-20 1991-09-20
US79192491A 1991-11-14 1991-11-14
US791924 1991-11-14

Publications (2)

Publication Number Publication Date
EP0587806A1 EP0587806A1 (en) 1994-03-23
EP0587806A4 true EP0587806A4 (en) 1995-04-26

Family

ID=27560239

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92914704A Withdrawn EP0587806A4 (en) 1991-05-21 1992-05-20 Therapeutic and diagnostic methods based on neurotrophin-4 expression.

Country Status (8)

Country Link
EP (1) EP0587806A4 (en)
JP (1) JPH08510987A (en)
AU (1) AU674659B2 (en)
CA (1) CA2109598A1 (en)
IE (1) IE921636A1 (en)
NZ (1) NZ242813A (en)
PT (1) PT100511A (en)
WO (1) WO1992020365A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE140966T1 (en) * 1990-09-25 1996-08-15 Genentech Inc NEW NEUROTROPIC FACTOR
AU4535993A (en) * 1992-06-12 1994-01-04 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
FI991197A0 (en) * 1999-05-27 1999-05-27 Mart Saarma Neurotropic factors in the treatment of pelvic peripheral dysfunction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005254A1 (en) * 1990-09-25 1992-04-02 Genentech, Inc. Novel neurothrophic factor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
IL101661A (en) * 1991-04-23 1998-02-08 Regeneron Pharma Method for detecting, identifying or measuring agents having neurotrophin activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005254A1 (en) * 1990-09-25 1992-04-02 Genentech, Inc. Novel neurothrophic factor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NANCY Y. IP ET AL.: "Mammalian neurotrophin-4: Structure, chromosomal localization, tissue distribution, and receptor specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 89, no. 7, 1 April 1992 (1992-04-01), WASHINGTON US, pages 3060 - 3064 *
See also references of WO9220365A1 *

Also Published As

Publication number Publication date
EP0587806A1 (en) 1994-03-23
CA2109598A1 (en) 1992-11-26
WO1992020365A1 (en) 1992-11-26
AU674659B2 (en) 1997-01-09
AU2302192A (en) 1992-12-30
NZ242813A (en) 1996-09-25
JPH08510987A (en) 1996-11-19
IE921636A1 (en) 1992-12-02
PT100511A (en) 1993-09-30

Similar Documents

Publication Publication Date Title
EP0656183A3 (en) Patient care system.
EP0684784A4 (en) Cardiac monitoring and diagnostic system.
EP0601775A3 (en) Cardiac event detection in implantable medical devices.
EP0647434A3 (en) Tissue piercing members.
EP0596962A4 (en) Therapeutic compositions and methods.
EP0571184A3 (en) Reinforced catheter probe.
IL106037A0 (en) Therapeutic and diagnostic methods based on neurotrophin-4-expression
EP0604931A3 (en) Medical laser apparatus and diagnosing/curing apparatus using the medical laser apparatus.
ZA935575B (en) Therapeutic agent and its use.
ZA94343B (en) Diagnostic imaging method and device.
GB2280036B (en) Therapy tomograph
EP0640093A4 (en) Human crabp-i and crabp-ii.
EP0370115A4 (en) Catheter for diagnosis and therapy
EP0587806A4 (en) Therapeutic and diagnostic methods based on neurotrophin-4 expression.
GB2298571B (en) Durable patient chair
ZA928730B (en) Therapeutic and diagnostic methods based on tissue-specific NT-3 expression and receptor binding.
EP0666745A4 (en) Diagnosis and therapy for parkinson's disease.
ZA93694B (en) Pharmaceutical treatments.
GB9217124D0 (en) Medical treatment
EP0644716A4 (en) Medical uses of trioxolane and diperoxide compounds.
ZA923716B (en) Therapeutic and diagnostic methods based on neurotrophin-4 expression
GB9120768D0 (en) Diagnostic and prognastic materials and methods
ZA934284B (en) Therapeutic and diagnostic methods based on neurotrophin-4 expression
HU9200644D0 (en) Medical preparatives
ZA932458B (en) Naphtoquinones and their use.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/62

A4 Supplementary search report drawn up and despatched

Effective date: 19950309

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YANCOPOULOS, GEORGE, D.

Inventor name: IP, NANCY

Inventor name: PERSSON, HAKAN BENGT

Inventor name: IBANEZ MOLINER, CARLOS, FERNANDO

Inventor name: HALLBOOK, FINN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PERSSON, LAURA BETH

Owner name: PERSSON, MAX PHILIP

Owner name: MC INTYRE, KATHERINE ROWE

Owner name: IBANEZ MOLINER, CARLOS FERNANDO

Owner name: HALLBOOK, FINN

Owner name: REGENERON PHARMACEUTICALS, INC.

17Q First examination report despatched

Effective date: 19960318

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970628